ID   SuSa-CP
AC   CVCL_B7BN
SY   SuSa cisR
DR   Wikidata; Q112930434
RX   PubMed=2144165;
CC   Doubling time: 29.8 +- 0.8 hours (PubMed=2144165).
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Derived from site: In situ; Testis; UBERON=UBERON_0000473.
DI   NCIt; C3877; Testicular teratoma
DI   ORDO; Orphanet_363483; Testicular teratoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_L280 ! SuSa
SX   Male
AG   30Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 29-06-23; Version: 4
//
RX   PubMed=2144165; DOI=10.1016/0277-5379(90)90133-e;
RA   Walker M.C., Povey S., Parrington J.M., Riddle P.N., Knuechel R.,
RA   Masters J.R.W.;
RT   "Development and characterization of cisplatin-resistant human
RT   testicular and bladder tumour cell lines.";
RL   Eur. J. Cancer 26:742-747(1990).
//